{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:18:31Z","timestamp":1792790311474,"version":"4.5.0"},"posted":{"date-parts":[[2026,9,17]]},"group-title":"Biochemistry","reference-count":39,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.biorxiv.org\/about\/FAQ#license"}],"funder":[{"name":"National Heart Lung and Blood Institute","award":["HL173026"],"award-info":[{"award-number":["HL173026"]}],"id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Heart Lung and Blood Institute","award":["HL169804"],"award-info":[{"award-number":["HL169804"]}],"id":[{"id":"https:\/\/ror.org\/012pb6c26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,9,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection. It is a leading cause of in-hospital mortality. The multicenter Acute Respiratory Distress Syndrome Network Statins for Acutely Injured Lungs from Sepsis (ARDSNet-SAILS) trial found that rosuvastatin (RS) did not improve clinical outcomes in patients with sepsis-associated ARDS and may increase hepatic and renal dysfunction. We evaluated associations of plasma cholesterol ester transfer protein (CETP) activity and Serum Amyloid A (SAA) levels with survival and clinical outcomes using plasma samples and clinical data from ARDSNet-SAILS trial.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This secondary analysis included clinical data and plasma samples from 471 ARDSNet-SAILS participants, randomized to placebo (PL) or RS. Plasma CETP activities and SAA levels were measured at enrollment (Day 0, n=466) and Days 3 (n=425) and 6 (n=342). Treatment effects were assessed using linear mixed models, and associations with survival and outcomes using Cox, linear, beta-binomial, and zero-inflated negative binomial regression models.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CETP activities were significantly higher in the survivors compared to non-survivors on days 0, 3, and 6 of analysis, in both the treatment groups (p&lt;0.01). Higher Day 0 and Day 3 CETP activities in PL patients independently predicted improved survival, with every 3-unit increase in activity associated with 18\u201319% lower mortality risk. In the RS treatment group, higher CETP at Day 0, Day 3, and Day 6 was significantly associated with reduced hazard of mortality (p=0.039, 0.005, and 0.022, and hazard ratios = 0.87, 0.82, and 0.80, respectively, for Days 0, 3, and 6). Higher CETP values on Days 3 and 6 were also significantly negatively associated with APACHE score and positively associated with increased renal dysfunction-free days (p=0.001). Plasma SAA levels decreased significantly over time in both treatment groups (p&lt;0.0001). In the PL group, higher plasma SAA levels were associated with a lower hazard of mortality. Accordingly, survivors had significantly higher plasma SAA levels than non-survivors at Day 0 (p=0.005). Higher SAA levels at Days 0 and 3 were also inversely correlated with APACHE scores, while Day 0 SAA levels were positively associated with overall organ dysfunction-free days (p=0.002). In contrast, in the RS group, higher plasma SAA levels were associated with an increased hazard of mortality, reaching statistical significance at Day 6 (p&lt;0.01). Despite this, higher SAA levels in the RS group were positively associated with renal dysfunction-free days (Day 3, p=0.004; Day 6, p=0.006), hepatic dysfunction-free days (Days 0, 3, and 6; all p\u22640.001), and overall organ dysfunction-free days (Day 0, p=0.017; Days 3 and 6, both p&lt;0.001). Analysis of SAA levels in FPLC fractions demonstrated higher SAA levels in the HDL fraction among survivors compared with non-survivors in the PL group on Days 0 and 3; however, this difference was not observed in the RS group.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Taken together, these findings identify plasma CETP activities and early SAA levels as stable prognostic biomarkers associated with improved survival and reduced disease severity in sepsis. However, while both CETP activity and SAA levels were unaffected by RS treatment, it appeared to modify the association between SAA and mortality.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.09.14.751535","type":"posted-content","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:05:14Z","timestamp":1789643114000},"source":"Crossref","is-referenced-by-count":0,"title":["Preserved CETP Activity and Early Serum Amyloid A are Associated with Improved Outcomes in Sepsis-Associated ARDS"],"prefix":"10.64898","author":[{"given":"Ailing","family":"Ji","sequence":"first","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osemwenoyenmwen","family":"Abu","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke W.","family":"Meredith","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clairity H.","family":"Voy","sequence":"additional","affiliation":[{"name":"Physiology, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.C.","family":"Bruno","sequence":"additional","affiliation":[{"name":"Surgery, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky 40536, USA"},{"name":"Physiology, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Hawk","sequence":"additional","affiliation":[{"name":"Dr. Bing Zhang Department of Statistics, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene E.","family":"Starr","sequence":"additional","affiliation":[{"name":"Internal Medicine, University of Kentucky, Lexington, Kentucky 40536, USA"},{"name":"Surgery, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preetha","family":"Shridas","sequence":"additional","affiliation":[{"name":"Saha Cardiovascular Research Center, University of Kentucky, Lexington, Kentucky 40536, USA"},{"name":"Internal Medicine, University of Kentucky, Lexington, Kentucky 40536, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026092109550973000_2026.09.14.751535v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.06.030"},{"key":"2026092109550973000_2026.09.14.751535v1.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201003-0423OC"},{"key":"2026092109550973000_2026.09.14.751535v1.3","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.7part2.85S"},{"key":"2026092109550973000_2026.09.14.751535v1.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401520"},{"key":"2026092109550973000_2026.09.14.751535v1.5","doi-asserted-by":"crossref","unstructured":"Marotti KR , Castle CK , Boyle TP , et al: Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993; 364(6432):73-75","DOI":"10.1038\/364073a0"},{"key":"2026092109550973000_2026.09.14.751535v1.6","doi-asserted-by":"crossref","unstructured":"Okamoto H , Yonemori F , Wakitani K , et al: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000; 406(6792):203-207","DOI":"10.1038\/35018119"},{"key":"2026092109550973000_2026.09.14.751535v1.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGENETICS.108.817304"},{"key":"2026092109550973000_2026.09.14.751535v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.23.2777"},{"key":"2026092109550973000_2026.09.14.751535v1.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1157OC"},{"key":"2026092109550973000_2026.09.14.751535v1.10","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0b013e31816e30fd"},{"key":"2026092109550973000_2026.09.14.751535v1.11","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1784014"},{"key":"2026092109550973000_2026.09.14.751535v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902113400607"},{"key":"2026092109550973000_2026.09.14.751535v1.13","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200001000-00012"},{"key":"2026092109550973000_2026.09.14.751535v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.2.293"},{"key":"2026092109550973000_2026.09.14.751535v1.15","doi-asserted-by":"crossref","unstructured":"Ji A , Meredith LW , Shridas P : Serum Amyloid A: A Double-Edged Sword in Health and Disease. Int J Mol Sci 2025; 26(10)","DOI":"10.3390\/ijms26104528"},{"key":"2026092109550973000_2026.09.14.751535v1.16","doi-asserted-by":"crossref","unstructured":"Ji A , Trumbauer AC , Noffsinger VP , et al: Deficiency of Acute-Phase Serum Amyloid A Exacerbates Sepsis-Induced Mortality and Lung Injury in Mice. Int J Mol Sci 2023; 24(24)","DOI":"10.3390\/ijms242417501"},{"key":"2026092109550973000_2026.09.14.751535v1.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.704254"},{"key":"2026092109550973000_2026.09.14.751535v1.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.2010.02269.x"},{"issue":"9","key":"2026092109550973000_2026.09.14.751535v1.19","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/CIRCULATIONAHA.120.048568","article-title":"Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis","volume":"143","year":"2021","journal-title":"Circulation"},{"key":"2026092109550973000_2026.09.14.751535v1.20","doi-asserted-by":"crossref","first-page":"100011","DOI":"10.1194\/jlr.RA120000704","article-title":"Human cholesteryl ester transfer protein lacks lipopolysaccharide transfer activity, but worsens inflammation and sepsis outcomes in mice","volume":"62","year":"2021","journal-title":"J Lipid Res"},{"key":"2026092109550973000_2026.09.14.751535v1.21","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.178681"},{"issue":"5","key":"2026092109550973000_2026.09.14.751535v1.22","doi-asserted-by":"crossref","first-page":"100365","DOI":"10.1016\/j.jlr.2023.100365","article-title":"Serum amyloid A augments the atherogenic effects of cholesteryl ester transfer protein","volume":"64","year":"2023","journal-title":"J Lipid Res"},{"issue":"2","key":"2026092109550973000_2026.09.14.751535v1.23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11883-020-00901-4","article-title":"High-Density Lipoproteins and Serum Amyloid A (SAA)","volume":"23","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"2026092109550973000_2026.09.14.751535v1.24","first-page":"e196","article-title":"One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial","volume":"44","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026092109550973000_2026.09.14.751535v1.25","doi-asserted-by":"crossref","unstructured":"Ridker PM , Danielson E , Fonseca FA , et al: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009; 373(9670):1175-1182","DOI":"10.1016\/S0140-6736(09)60447-5"},{"issue":"5","key":"2026092109550973000_2026.09.14.751535v1.26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.tem.2020.01.003","article-title":"A Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis","volume":"31","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2026092109550973000_2026.09.14.751535v1.27","doi-asserted-by":"crossref","first-page":"16764","DOI":"10.1038\/s41598-018-35261-2","article-title":"CETP genetic variant rs1800777 (allele A) is associated with abnormally low HDL-C levels and increased risk of AKI during sepsis","volume":"8","year":"2018","journal-title":"Sci Rep"},{"key":"2026092109550973000_2026.09.14.751535v1.28","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.110.207977"},{"key":"2026092109550973000_2026.09.14.751535v1.29","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-009-1609-y"},{"key":"2026092109550973000_2026.09.14.751535v1.30","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000171183.79525.6B"},{"key":"2026092109550973000_2026.09.14.751535v1.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706628"},{"key":"2026092109550973000_2026.09.14.751535v1.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1206797"},{"key":"2026092109550973000_2026.09.14.751535v1.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706444"},{"key":"2026092109550973000_2026.09.14.751535v1.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609581"},{"key":"2026092109550973000_2026.09.14.751535v1.35","doi-asserted-by":"publisher","DOI":"10.2165\/11315710-000000000-00000"},{"key":"2026092109550973000_2026.09.14.751535v1.36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00744.x"},{"key":"2026092109550973000_2026.09.14.751535v1.37","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm496"},{"key":"2026092109550973000_2026.09.14.751535v1.38","doi-asserted-by":"publisher","DOI":"10.3109\/13506129.2011.654294"},{"key":"2026092109550973000_2026.09.14.751535v1.39","first-page":"244","article-title":"HDL in sepsis - risk factor and therapeutic approach","volume":"6","year":"2015","journal-title":"Front Pharmacol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.09.14.751535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:55:23Z","timestamp":1790009723000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.09.14.751535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":39,"URL":"https:\/\/doi.org\/10.64898\/2026.09.14.751535","relation":{},"subject":[],"published":{"date-parts":[[2026,9,17]]},"subtype":"preprint"}}